Tesofensine is an experimental weight loss drug that works by blocking the reabsorption of three brain chemicals involved in appetite and energy: dopamine, norepinephrine, and serotonin. In a Phase II clinical trial, the middle dose (0.5 mg) produced an average body weight loss of 9.2% over 24 weeks on top of what diet alone achieved, leading researchers to suggest it could be twice as effective as weight loss drugs that were available at the time. It is not currently approved by the FDA.
How Tesofensine Works in the Brain
Most weight loss drugs target one brain signaling pathway. Tesofensine targets three at once. By preventing nerve cells from reabsorbing dopamine, norepinephrine, and serotonin, it keeps higher levels of all three chemicals active in the brain simultaneously. This “triple reuptake inhibition” is what sets it apart from older appetite suppressants that typically act on just one or two of these pathways.
The appetite-suppressing effect comes primarily from two of those pathways. Increased norepinephrine activity stimulates receptors that dampen hunger signals, while elevated dopamine activity engages reward circuits in a way that reduces the drive to eat. Together, these effects make people feel less hungry and more satisfied with smaller amounts of food. Animal research confirms that blocking either of these pathways individually weakens the drug’s effect, meaning both need to be active for full appetite suppression.
Beyond appetite, the boost in norepinephrine has a secondary effect on energy expenditure. It can increase thermogenesis, the process by which your body generates heat and burns calories, particularly through activation of fat tissue. Elevated dopamine also appears to increase physical activity levels. That said, researchers describe the metabolic rate increase as small. The primary driver of weight loss is reduced food intake, not a faster metabolism.
Weight Loss Results From Clinical Trials
The most cited trial enrolled 203 obese adults with a BMI between 30 and 40. All participants followed a calorie-restricted diet and took either a placebo or one of three tesofensine doses (0.25 mg, 0.5 mg, or 1.0 mg) once daily for 24 weeks. The results were dose-dependent and striking:
- Placebo plus diet: 2.0% body weight loss
- 0.25 mg plus diet: 4.5% additional weight loss beyond placebo
- 0.5 mg plus diet: 9.2% additional weight loss beyond placebo
- 1.0 mg plus diet: 10.6% additional weight loss beyond placebo
The jump from 0.25 mg to 0.5 mg was substantial, but the additional benefit of going from 0.5 mg to 1.0 mg was relatively modest. This matters because higher doses also brought more side effects, making the 0.5 mg dose the apparent sweet spot for balancing efficacy and tolerability. About 79% of participants completed the full 24-week study, a solid retention rate for an obesity trial.
How It Was Originally Discovered
Tesofensine wasn’t designed as a weight loss drug. It was initially developed to treat Parkinson’s disease and Alzheimer’s disease, where boosting dopamine, norepinephrine, and serotonin could theoretically improve motor function and cognition. Four randomized trials tested the drug across both conditions, enrolling nearly 1,000 patients total. The drug didn’t show enough benefit for those neurological conditions, but researchers noticed a consistent and unexpected pattern: patients kept losing weight.
Among obese patients in those trials, weight changes after just 14 weeks ranged from a 1.7% loss at the lowest dose to a 3.7% loss at the highest dose, with no diet program in place. At the 1.0 mg dose, about 32% of obese participants lost 5% or more of their body weight in that short window. That side effect became the drug’s new purpose, and development pivoted entirely toward obesity treatment.
Side Effects and Safety Concerns
The most common side effects in trials were dry mouth, nausea, constipation, hard stools, diarrhea, and insomnia. These are consistent with what you’d expect from a drug that increases norepinephrine and serotonin activity throughout the body.
The bigger concern is cardiovascular. Because norepinephrine stimulates the sympathetic nervous system (your “fight or flight” response), tesofensine raises heart rate in a dose-dependent way. In the Parkinson’s and Alzheimer’s trials, heart rate increased by about 4 to 7 beats per minute at moderate to high doses. In the obesity trial, the 0.5 mg dose raised heart rate by 7.4 beats per minute compared to placebo. Blood pressure did not significantly increase at the 0.25 mg or 0.5 mg doses, but the cardiovascular signal has remained a focus of concern. Animal research has explored whether pairing tesofensine with blood pressure medication could preserve the appetite suppression while offsetting the heart rate increase, and early results suggest it can.
How It Compares to GLP-1 Drugs
Tesofensine and GLP-1 receptor agonists like semaglutide work through completely different mechanisms. GLP-1 drugs mimic a gut hormone that increases insulin secretion, slows stomach emptying, and suppresses appetite through signals originating in the digestive system. Tesofensine works entirely in the central nervous system, adjusting brain chemistry rather than gut hormones. In practical terms, GLP-1 drugs tend to cause gastrointestinal side effects like nausea, vomiting, and diarrhea, while tesofensine’s main concerns are cardiovascular, particularly elevated heart rate.
No head-to-head trials have directly compared the two. The newer GLP-1 drugs, particularly semaglutide at higher doses, have produced weight loss results in the range of 15% or more in Phase III trials, which exceeds what tesofensine showed in its Phase II data. However, tesofensine’s Phase II results were considered impressive at the time, and it takes a different enough approach that some researchers see potential value in its development as an alternative or complement to gut-hormone-based therapies.
Current Approval and Development Status
Tesofensine is not approved by the FDA for any indication. It received an FDA orphan drug designation in March 2021 as a fixed-dose combination with a heart rate-lowering medication for the treatment of Prader-Willi syndrome, a rare genetic condition that causes extreme hunger and obesity. That designation signals ongoing interest but does not mean the drug is close to market approval.
A Phase III trial has been registered in Mexico, sponsored by a Mexican pharmaceutical company, evaluating tesofensine for obesity. The drug has not completed the Phase III process required for broad regulatory approval in any major market. Without confirmed Phase III results demonstrating both efficacy and long-term safety, particularly regarding cardiovascular effects, tesofensine remains investigational. It is sometimes available through compounding pharmacies or clinics outside of standard regulatory channels, but this use falls outside of any formal approval.